Merck, a leading science and technology company, today announced that results from FORWARD, a five-year, multicentre Phase II study of sprifermin, a recombinant human fibroblast growth factor-18, in patients with symptomatic radiographic knee osteoarthritis (OA) were published online in the Journal of the American Medical Association (JAMA). ...
Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management....
Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up....
Exactech, a developer and producer of bone and joint restoration products for extremities, hip and knee, announced the launch of the new Vantage® Ankle Flat Cut Talus, an option for the Vantage Total Ankle Fixed Bearing System. This is the latest addition to its foot and ankle portfolio....
Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the first commercial placements of its Pure-Vu® System as part of its initial U.S. market launch targeting...
Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a study of the company’s ASCEND investigational drug-coated sinus balloon....
Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP. Analysis Illustrates the Significant and Independent Impact of High PrEP Use on HIV Diagnoses Rate in Major U.S. Cities -...
Amarin posted an updated Investor Presentation on October 2, 2019. ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced the presentation of detailed one-year results...
Net sales of $66.0 million, an increase of 3.3% year over year. Gross margin increased 170 basis points year over year to 57.9%. GAAP loss per share of $0.03; adjusted earnings per share of $0.08...